



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice – New Programs:** Alternative Chemoradiation Treatment for Lung Cancer
- **Cancer Drug Manual – Revised:** Abiraterone, Carfilzomib, Regorafenib, EPOCHR
- **Benefit Drug List – New:** Bevacizumab, Carboplatin, Cisplatin, Etoposide, Paclitaxel
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts – New:** LULAPE2RT Revised: BRAJCEFG, BRAJDC, BRAJFEC, BRAJFEC, BRINFCEFG, BRLACEFG, UGIPGEMABR, GOBEP, GOCXAJCAT, GOCXCATB, GOSADG, HNAVP, LYGDPR, UMYLENDEX, UMYLENMTN
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following program effective 1 August 2015:

Lung:

Alternative Chemoradiation Treatment for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (LULAPE2RT)

– A shorter course of cisplatin and etoposide is now available as a concurrent chemotherapy option for patients with locally advanced NSCLC. This alternative regimen has a higher total cumulative cisplatin dose (400 mg/m²) given over two cycles compared to the existing LULAPERT protocol (300 mg/m²) over two cycles concurrent with radiation and two cycles as consolidation. Concurrent chemotherapy without consolidative chemotherapy is a common practice in other jurisdictions. [Hanna N, et al. *J Clin Oncol* 2008;28:5755, Albain KS, et al. *J Clin Oncol* 2005;23(16 suppl):7014.] Therefore, it is important that this alternative regimen is available to allow patients to be eligible for appropriate clinical trials.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Abiraterone:

- Monograph: Precautions, Side Effects, Interactions and Dosing in Hepatic Failure have been updated in

CANCER DRUG MANUAL

the monograph

- Handout: Blood pressure monitoring added, high cholesterol monitoring removed (incidence of high cholesterol similar to placebo in clinical trials)

Carfilzomib Interim Monograph:

- New safety information on hypertensive and respiratory events added

Regorafenib Monograph and Handout:

- Expiry of bottle contents after opening has been extended from 28 days to 7 weeks based on new stability data

NEW ENTRY TO CHEMOTHERAPY PREPARATION AND STABILITY CHART

A new entry named **EPOCHR** has been added to provide information on a 3-in-1 solution containing etoposide, doxorubicin and vincristine. Cross-references have also been added to individual drug entries for these three drugs.

This preparation is part of an interim regimen (ULYEPOCHR) currently under review for funding at the BCCA.

BENEFIT DRUG LIST

NEW PROGRAMS

The following program has been added to the [Benefit Drug List](#) effective 1 August 2015:

Protocol Title	Protocol Code	Benefit Status
Treatment of locally advanced non-small cell lung cancer using alternative dosing of <i>cisplatin</i> and <i>etoposide</i> with radiation therapy	LULAPE2RT	Class I

REVISED PROGRAMS

The following program has been revised on the [Benefit Drug List](#) effective 1 August 2015:

Protocol Title	Protocol Code	Benefit Status
Primary treatment of metastatic or recurrent squamous cancer of the cervix with <i>bevacizumab</i> , <i>carboplatin</i> and <i>paclitaxel</i>	GOCXCATB	Class II (Previously Restricted)

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
LULAPE2RT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Locally Advanced Non-Small Cell Lung Cancer Using Alternative Dosing of CISplatin and Etoposide with Radiation Therapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJCEFG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and number of treatment cycles clarified</i>	Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
BRAJDC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Adjuvant Therapy for Breast Cancer Using DOCEtaxel and Cyclophosphamide
BRAJFEC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Number of treatment cycles clarified</i>	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BRAJFEC D	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Number of treatment cycles clarified</i>	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BRINCFEFG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
BRLACEFG	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and number of treatment cycles clarified</i>	Therapy for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil and Filgrastim
UGIPGEMABR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications clarified, brand added, maximum infusion time deleted</i>	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel-Nab (ABRAXANE®) and Gemcitabine
GOBEP	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Bleomycin dosing schedule clarified</i>	Treatment with Bleomycin, Etoposide, CISplatin for Ovarian Germ Cell Cancer
GOCXAJCAT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and emetogenicity clarify</i>	Primary Adjuvant Treatment of Adenocarcinoma/Adenosquamous Cancer of the Cervix with CARBOplatin and PACLitaxel Prior to Irradiation with or without CISplatin
GOCXCATB	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Protocol code and Eligibility revised</i>	Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel
GOSADG	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Space for dosage entry expanded</i>	Treatment of Uterine Sarcoma Cancer using DOCEtaxel and Gemcitabine

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
HNAVP	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Cisplatin infusion time clarified</i>	Palliative Chemotherapy for Advanced Head and Neck Squamous Cell Carcinoma with Weekly CISplatin
LYGDPR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Age deleted from Exclusions</i>	Treatment of Lymphoma with Gemcitabine, Dexamethasone and CISplatin with riTUXimab
UMYLENDEX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and dosing for dialysis clarified</i>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone
UMYLENMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Use of higher doses of lenalidomide at progression clarified, minor typo corrected on PPPO</i>	Maintenance Therapy of Multiple Myeloma Using Lenalidomide

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604.877.6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 Victoria Kletas, MSc (Clin Pharm)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN, BN, CON(c)
 Rob Watt, BSc (Pharm)